Foresite Capital Fund III L.P. 13D and 13G filings for Aclaris Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-11 3:12 pm Sale | 2021-12-31 | 13G | Aclaris Therapeutics, Inc. ACRS | Foresite Capital Fund III L.P. | 4,657,277 7.600% | -1,954,904 (-29.57%) | Filing |
| 2021-02-11 2:56 pm Purchase | 2021-02-05 | 13G | Aclaris Therapeutics, Inc. ACRS | Foresite Capital Fund III L.P. | 6,612,181 13.700% | 4,381,241 (+196.39%) | Filing |
| 2020-10-26 7:47 pm Purchase | 2020-10-20 | 13G | Aclaris Therapeutics, Inc. ACRS | Foresite Capital Fund III L.P. | 2,230,940 5.200% | 2,230,940 (New Position) | Filing |